Persistent pain is common in rheumatoid arthritis. But patient-reported outcomes tools can help clinicians determine a care plan.

US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...

Arthritis in your 20s might seem unusual, but it's becoming more frequent. Check out these 7 warning signs and symptoms of ...

Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...

Treatment for arthritis is mainly focused on symptom management and slowing the progression of the disease, says Dr Vishal ...

Arthritis, often thought to be an ailment of the elderly, is an autoimmune disease prevalent across all ages, particularly in ...

The following is a summary of “Opioid Use and Healthcare Utilization in Adults With Psoriatic Arthritis and Ankylosing ...

Symptoms of psoriatic arthritis are similar to rheumatoid arthritis and include, pain, swelling and stiffness in one or more ...

The Food and Drug Administration (FDA) has expanded the approval of Bimzelx (bimekizumab-bkzx) to include 3 new indications.

Objectives Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The objective was to assess the efficacy of apremilast in early oligoarticular PsA. Methods FOREMOST (NCT03747939) ...

Psoriatic arthritis surgery could involve removing damaged tissue or bone or replacing a joint with severe damage. Learn more here.